Tuesday, May 3
7:00 am Registration Open (Plaza Level Lobby)
8:00 am Recommended Pre-Conference Workshops and Symposium*
On Tuesday, May 3, 2022 Cambridge Healthtech Institute is pleased to offer nine pre-conference workshops scheduled across three time slots (8:00-10:00 am, 10:30 am-12:30 pm, and 1:45-3:45 pm) and a Symposium from 8:25 am-3:45 pm. All are designed to be instructional, interactive and provide in-depth information on a specific topic. They allow for one-on-one interaction and provide a great way to explain more technical aspects that would otherwise not be covered during the main conference tracks that take place Wednesday-Thursday.
*Separate registration required. See Workshop page and Symposium page for details.
3:45 pm Session Break and Transition to Plenary Keynote
4:00 pm Welcome by Conference Organizer
Allison Proffitt, Editorial Director, Bio-IT World
4:05 pm Innovative Practices Award
4:30 pm Ask What IT Can Do for Bio...and What Bio Can Do for IT
George M. Church, PhD, Robert Winthrop Professor, Genetics, Harvard Medical School
IT for Bio: In May 2021, one haploid human genome (3.055 billion bp) was sequenced completely, but zero diploid. We have 7.7 billion diploid humans yet to be sequenced and correlated with their environments and traits in the Personal Genome Project. Plus, at least one genome from each of over 8.7 million eukaryotic species in the Earth Biogenome project. Plus, monitoring pathogenic and commensal bacteria, allergens, and viruses in the BioWeatherMap. Plus, ancient DNA. We are counting RNA molecules per cell in most (or all) cell types in humans, mice, and many other species throughout development and connectome (with imaging resolution up to 20 nm).
Bio for IT: Reading and writing DNA has improved exponentially in cost (at least 60 million fold) and is increasingly used for storing non-biological data. The record for editing DNA in vivo is now 24,000 edits per cell and for storing data in vivo is about 1 terabyte per mouse. Enormous chemical and biological 'libraries' can perform 'Natural Computing' for tasks far beyond current von-Neumann silicon and quantum computers. The combination of these – machine learning + megalibraries (ML-ML) is already having commercial impact (e.g. Nabla, Manifold, Dyno, Patch).
5:45 pm Welcome Reception in the Exhibit Hall with Poster Viewing (Auditorium/Hall C)
7:00 pm Close of Day
Wednesday, May 4
7:00 am Registration Open and Morning Coffee (Plaza Level Lobby)
8:00 am Welcome by Conference Organizer
Allison Proffitt, Editorial Director, Bio-IT World
8:15 am Accessing and Securing the Data that Drives Breakthroughs
Allison Proffitt, Editorial Director, Bio-IT World
Rachana Ananthakrishnan, Executive Director, Globus, University of Chicago
Ari E. Berman, PhD, CEO, BioTeam, Inc.
Jonathan C. Silverstein, Chief Research Informatics Officer & Professor, Biomedical Informatics, University of Pittsburgh
Rebecca F. Rosen, PhD, Director, Office of Data Science and Sharing, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health
Life sciences research is generating massive amounts of data that should be accessible to collaborators and colleagues to enable breakthrough discoveries. However, ensuring sensitive data are shared securely in a manner that protects patient privacy and complies with myriad regulations is a daunting task, which often slows the pace of research. Our panel of leading practitioners will share insights on the challenges and best practices of managing protected research data.
9:30 am Coffee Break in the Exhibit Hall with Poster Viewing (Auditorium/Hall C)
10:15 am Organizer's Remarks
10:20 am Chairperson's Remarks
Subha Madhavan, PhD, Head of Data Science, Oncology R&D, AstraZeneca
10:25 am How Is AI Transforming Oncology Research and Care Delivery?
Subha Madhavan, PhD, Head of Data Science, Oncology R&D, AstraZeneca
Thomas Clozel, MD, Co-Founder & CEO, OWKIN, Inc.
Jill Barnholtz-Sloan, PhD, Associate Director for Informatics and Data Science (CBIIT) & Senior Investigator (DCEG), National Cancer Institute
James L. Chen, MD, Senior Vice President, Cancer Informatics, Tempus Labs, Inc.
Artificial intelligence (AI) has captured the society’s imagination in terms of having the potential to improve our lives. There is an increasing interest in the applications of AI in healthcare to improve disease diagnosis, management, and the development of effective therapies. Given the large number of patients diagnosed with cancer and significant amount of and variety of data generated during cancer treatment, there is an increased focus in the application of AI to improve oncologic research and care. In this panel we discuss current applications, pitfalls, and future directions for applications of AI in oncology.
10:25 am PANEL DISCUSSION: How Is AI Transforming Oncology Research and Care Delivery?
Subha Madhavan, PhD, Head of Data Science, Oncology R&D, AstraZeneca
Thomas Clozel, MD, Co-Founder & CEO, OWKIN, Inc.
Jill Barnholtz-Sloan, PhD, Associate Director for Informatics and Data Science (CBIIT) & Senior Investigator (DCEG), National Cancer Institute
James L. Chen, MD, Senior Vice President, Cancer Informatics, Tempus Labs, Inc.
Artificial intelligence (AI) has captured the society’s imagination in terms of having the potential to improve our lives. There is an increasing interest in the applications of AI in healthcare to improve disease diagnosis, management, and the development of effective therapies. Given the large number of patients diagnosed with cancer and significant amount of and variety of data generated during cancer treatment, there is an increased focus in the application of AI to improve oncologic research and care. In this panel we discuss current applications, pitfalls, and future directions for applications of AI in oncology.
12:25 pm Automating Biomarker and Phenotype Extraction With Natural Language Processing in a Real-World Precision Oncology Platform (Innovative Practices Award Winner)
Irfan Shah, Director, Business Development, Guardant Health
Paul Milligan, PhD, Product & Strategy Director, IQVIA NLP
In the area of precision oncology, the more availability of high-quality clinical data that enables additional stratified insights to be gleaned, the better. This is the driving force behind an initiative by Guardant Health in partnership with IQVIA, Inc. to use state of the art text mining and Natural Language Processing (NLP) to structure and normalize complex clinical variables from clinical documents in the real-world clinical-genomic platform—Guardant INFORM. Built on Guardant360 liquid biopsy results, Guardant INFORM combines large volumes of genomic and clinical data to help accelerate research and development of next generation cancer therapeutics. Using NLP, key information such as TNM stage, biomarker profile, tumor histology, smoking history and performance status is now extracted from the patient narrative and transformed to normalized, structured data with precision of up to 100% for certain variables. By coupling deep phenotypic information with liquid biopsy results, more targeted drug development, better clinical trial optimization and more powerful post market research are all enabled.
12:55 pm Session Break and Transition to Luncheon Presentation
The power of NLP enables access to the information stored in unstructured clinical documentation. Structuring and understanding this rich information is a crucial first step towards accelerating the translation of cancer treatments from research to practice. NLP technology is becoming increasingly crucial as therapeutic options and access to individual-level health information increase.
We are excited to bring industry leaders together to discuss how NLP is being applied to cancer research.
1:50 pm Refreshment Break in the Exhibit Hall with Poster Viewing (Auditorium/Hall C)
2:40 pm AI in Cancer Genomics
Nardev Ramanathan, PhD, Senior Analyst, Lux Research
The capabilities of artificial intelligence (AI) for pattern recognition of complex datasets can be employed to extract relevant insights from genomic data for understanding the probability of cancer manifestation and early detection, as well as for designing precision therapies to improve treatment outcomes. This talk will discuss new and emerging applications of AI in precision oncology that show great promise for better patient outcomes.
3:10 pm Breakthrough AI to Find 6x More Undiagnosed and Miscoded Cancer Patients with Cachexia at Scale
Judith Sayers, MRCS Surgical Training Fellow, NHS Lothian
This presentation will demonstrate how Pangaea's novel unsupervised AI has been found to discover clinical features characterizing cachexia in cancer patients, which helped with earlier detection of 6x more cancer patients with cachexia, who were undiagnosed, miscoded or at risk. These findings have the potential to reduce treatment costs by 50% and to save $1 billion annually, in the UK.
3:40 pm AI Applications in Multiplex Tissue Imaging for Precision Oncology
Jeremy Goecks, PhD, Associate Professor of Biomedical Engineering and Section Head for Cancer Data Science, Oregon Health & Science University
Single-cell spatial multiplex tissue imaging (MTI) assays such as cyclic immunofluorescence, imaging mass cytometry, and CODEX have the potential to yield more accurate biomarkers for precision oncology. In the talk, I will share (a) an end-to-end software analysis workflow for MTI that uses AI/machine learning approaches to deeply characterize tumors and (b) application of this workflow to identify candidate spatial biomarkers associated with overall survival and therapeutic response.
At Owkin, we are using federated infrastructure to access multimodal data from our growing network of European and American hospitals, and applying AI to enable precision approaches to oncology and other diseases. Utilizing these resources, we are building biomarkers for patient selection, helping pharma accelerate clinical development, and discovering drug targets based on novel disease subtypes.
4:10 pm Sponsored Presentation (Opportunity Available)
4:40 pm Best of Show Awards Reception in the Exhibit Hall with Poster Viewing (Auditorium/Hall C)
6:00 pm Close of Day
Thursday, May 5
7:30 am Registration Open and Morning Coffee (Plaza Level Lobby)
8:00 am Welcome by Conference Organizer
Allison Proffitt, Editorial Director, Bio-IT World
8:15 am Leveraging Large-Scale Human Data to Advance and Accelerate Drug Discovery
Shankar Subramaniam, PhD, Distinguished Professor of Bioengineering; Professor of Chemistry, Biochemistry and Nanotechnology; Adjunct Professor of Cellular & Molecular Medicine, University of California at San Diego
Advances in genomics technologies have led to generation of massive amounts of human data. This has catalyzed new insights into cellular processes in the normal and disease state and facilitated the search for safe and effective medicines. The UK Biobank, All of US and TopMed initiatives are exemplars of this approach. We highlight examples from our lab where meaningful insights have been obtained advancing our understanding of disease biology and its pharmacological application.
9:30 am Coffee Break in the Exhibit Hall with Poster Viewing (Auditorium/Hall C)
10:15 am Organizer's Remarks
10:20 am Chairperson's Remarks
Julian Hong, MD, Assistant Professor, Department of Radiation Oncology, University of California, San Francisco
10:25 am Making AI Useful in the Oncology Clinic: Overcoming Barriers to Adoption
Julian Hong, MD, Assistant Professor, Department of Radiation Oncology, University of California, San Francisco
Artificial intelligence (AI) has generated significant enthusiasm and work, but clinical implementation and impact on patient care remain limited. We discuss our experience in deployment and healthcare provider feedback during the SHIELD-RT randomized study at Duke University (https://ascopubs.org/doi/10.1200/JCO.20.01688; 2021 Bio-IT World Innovative Practices Award winner) to provide insights into overcoming the challenges of integrating AI into practice. This talk builds on our prior presentation at Bio-IT World 2021 to discuss the practical details of deployment.
10:55 am CANCELLED: Can AI be Empathetic in a Cancer Patient's Journey?
Dr. Naila Siddiqui Kamal, Senior Lecturer, Obstetrics & Gynaecology, Imperial College London
As we move towards automation and use of technology-enabled healthcare, some groups are skeptical about AI and its emotional Intelligence capabilities in the context of Cancer. This talk will discuss the role of AI-based solutions that actually surpass human expectations in ensuring cancer patients have an empathetic and effective journey.
10:55 am The CRISPR Revolution: From Science Fiction to DNA Surgery
Kevin Davies, PhD, Executive Editor, The CRISPR Journal; Author, Editing Humanity: The CRISPR Revolution and the New Era of Genome Editing
In an e-mail exchange in 2001, a pair of European microbiologists agreed on the acronym “CRISPR” to describe a puzzling genomic motif in some bacteria. Less than two decades later, Jennifer Doudna and Emmanuelle Charpentier shared the Nobel Prize for Chemistry for the development of the CRISPR “genetic scissors”. This remarkable technology for genome editing has delivered an essential cure for patients with sickle-cell disease and other genetic disorders. It has also sparked international alarm and controversy over the birth of the first “CRIPSR babies” and the dismal prospect of designer babies. Kevin Davies, the founding editor of Bio-IT World, has chronicled the CRISPR revolution in his latest book, Editing Humanity. In this special presentation on the 20th anniversary of the Bio-IT World conference, he shares revealing stories of the heroes and heroines of CRISPR and the ensuing patent drama; details the latest clinical advances in the treatment of Mendelian disorders; examines the CRISPR babies scandal and its aftermath; and considered new genome editing platforms and applications from gene-edited crops to CRISPR kitties.
Artificial intelligence(AI) and deep learning (DL) are advancing oncology research and personalized treatments. Availability of huge number of datasets, novel AI and DL models help in early cancer detection, diagnosis, classification and grading and molecular characterization of tumors, prediction of patient outcomes. With technology and scientific expertise we help our customers in building AI/ML enabled data platforms for multi-modal data analysis in clinical care, molecular biology and clinical research.
1:05 pm Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own
1:50 pm Refreshment Break in the Exhibit Hall with Poster Viewing (Auditorium/Hall C)
2:35 pm Co-Chairperson's Remarks
H. Kim Lyerly, MD, FACS, George Barth Geller Distinguished Prof, Surgical Sciences & Applied Therapeutics, Duke University; Chair of Executive Council, Open Health Systems Laboratory (OHSL)
Anil Srivastava, President, Open Health Systems Laboratory (OHSL)
Martin Deutsch, Open Health Systems Laboratory (OHSL)
2:40 pm Pathways to Digital Twin in Medicine
H. Kim Lyerly, MD, FACS, George Barth Geller Distinguished Prof, Surgical Sciences & Applied Therapeutics, Duke University; Chair of Executive Council, Open Health Systems Laboratory (OHSL)
Eric Stahlberg, PhD, Director, Cancer Data Science Initiatives, Frederick National Laboratory for Cancer Research
Ken Buetow, PhD, Director, Computational Sciences and Informatics Program for Complex Adaptive Systems, Arizona State University
Kunhiparambath P. Haresh, MD, Asst Professor, All India Institute of Medical Sciences
Nicholas Siebenlist, MD, PhD, Solutions Leader, Public Health, C3 AI
Jane Yu, MD, PhD, Digital Architect, High Performance Computing, US Federal, Microsoft
B. Jayaram, PhD, Professor, International Centre of Excellence for Computational and Biomedical Sciences
Prashant Shah, Global Head of Artificial Intelligence, Health and Life Sciences & Senior Principal Engineer, Intel Corporation
The cancer patient digital twin is a multi-institutional public-private technology initiative providing clinical decision support at the point of care to neuro oncology. The cancer patient digital twin is a physician-driven, precision medicine application delivering AI/ML insights within the clinician workflow. The application delivers value out of the box with previously integrated data sets and customized clinician’s dashboards. The application provides an end-to-end solution leveraging reusable data models for rapid integration of new sets, further strengthening AI/ML performance, and supporting equitable healthcare models. Delivering these oncology insights at the point of care enhances patient outcomes, saves physicians times, and reduces medical costs.
4:10 pm Close of Conference